These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 22015718)

  • 1. PI3K/mTOR signaling regulates prostatic branching morphogenesis.
    Ghosh S; Lau H; Simons BW; Powell JD; Meyers DJ; De Marzo AM; Berman DM; Lotan TL
    Dev Biol; 2011 Dec; 360(2):329-42. PubMed ID: 22015718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
    Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
    Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
    Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
    Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR signaling feedback modulates mammary epithelial differentiation and restrains invasion downstream of PTEN loss.
    Ghosh S; Varela L; Sood A; Park BH; Lotan TL
    Cancer Res; 2013 Aug; 73(16):5218-31. PubMed ID: 23774212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta.
    Rahimi RA; Andrianifahanana M; Wilkes MC; Edens M; Kottom TJ; Blenis J; Leof EB
    Cancer Res; 2009 Jan; 69(1):84-93. PubMed ID: 19117990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of mTOR signaling affects cone function, cone structure and expression of cone specific proteins without affecting cone survival.
    Ma S; Venkatesh A; Langellotto F; Le YZ; Hall MN; Rüegg MA; Punzo C
    Exp Eye Res; 2015 Jun; 135():1-13. PubMed ID: 25887293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis.
    Morrison MM; Young CD; Wang S; Sobolik T; Sanchez VM; Hicks DJ; Cook RS; Brantley-Sieders DM
    PLoS Genet; 2015 Jul; 11(7):e1005291. PubMed ID: 26132202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.
    Shortt J; Martin BP; Newbold A; Hannan KM; Devlin JR; Baker AJ; Ralli R; Cullinane C; Schmitt CA; Reimann M; Hall MN; Wall M; Hannan RD; Pearson RB; McArthur GA; Johnstone RW
    Blood; 2013 Apr; 121(15):2964-74. PubMed ID: 23403624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
    Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
    Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.
    Werzowa J; Koehrer S; Strommer S; Cejka D; Fuereder T; Zebedin E; Wacheck V
    J Invest Dermatol; 2011 Feb; 131(2):495-503. PubMed ID: 21048785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
    Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA
    Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells.
    Song K; Shankar E; Yang J; Bane KL; Wahdan-Alaswad R; Danielpour D
    PLoS One; 2013; 8(5):e61896. PubMed ID: 23658701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53.
    Jung SH; Hwang HJ; Kang D; Park HA; Lee HC; Jeong D; Lee K; Park HJ; Ko YG; Lee JS
    Oncogene; 2019 Mar; 38(10):1639-1650. PubMed ID: 30337688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.
    Gulhati P; Bowen KA; Liu J; Stevens PD; Rychahou PG; Chen M; Lee EY; Weiss HL; O'Connor KL; Gao T; Evers BM
    Cancer Res; 2011 May; 71(9):3246-56. PubMed ID: 21430067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
    Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
    Song K; Cornelius SC; Reiss M; Danielpour D
    J Biol Chem; 2003 Oct; 278(40):38342-51. PubMed ID: 12876289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.